BUSINESSQUARTZ
Amgen is raising its outlook after beating earnings and dropping a weight loss drug
Amgen has increased its full-year revenue forecast to $38.2 billion–$39.4 billion following a 10% rise in second-quarter revenue to $10.1 billion. The company also announced the discontinuation of a weight loss drug.
Related Signal
Adjacent reporting
- Eli Lilly and Novo Nordisk raise profit outlook as weight-loss drug demand soars
- Eli Lilly beat earnings and raised its forecast as weight loss drug sales surged
- Cigna is raising its annual profit forecast on specialty drug strength
- Novo Nordisk is raising its full-year outlook as its weight loss pill keeps selling
- CVS Health's profit nearly tripled as it launched an Eli Lilly weight loss drug deal
- Eli Lilly stock surged after its next-generation weight loss drug posted record results